Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

RAPT Therapeutics, Inc. - Common Stock (NQ:RAPT)

11.70 -0.17 (-1.47%)
Streaming Delayed Price Updated: 10:04 AM EDT, Sep 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about RAPT Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Reports Second Quarter 2025 Financial Results
From RAPT Therapeutics, Inc.
Via GlobeNewswire
There are notable gap-ups and gap-downs in today's session.
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
RAPT Therapeutics Names Two Industry Veterans to its Board of Directors
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Rapt Therapeutics Get A Bullish Recommendation On ‘Significant Opportunity’ For Allergy Drug Candidate: Retail Worries About Cash Position
Clear Street’s initiated with a $3 price target, highlighting RPT904b as a “potentially best-in-class anti-IgE antibody.” 
Via Stocktwits
Topics ETFs
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
RAPT Therapeutics to Participate in Upcoming Investor Conferences
From RAPT Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
RAPT Therapeutics Reports First Quarter 2025 Financial Results
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics to Participate in Upcoming Investor Conferences
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Futures Slide As Bond Yields Jump To 6 Month High
US stock futures and Treasuries dropped as muted trading resumed after the Christmas holiday, with investors looking to initial jobless claims data and a government bond auction later on Thursday. 
Via Talk Markets
Topics Bonds Commodities Cryptocurrencies
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
This Progressive Analyst Turns Bullish; Here Are Top 3 Upgrades For Thursday
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Why RAPT Therapeutics Stock Gained Over 100% On Monday?
RAPT Therapeutics partners with Shanghai Jemincare to develop RPT904, a potential alternative to Xolair, for food allergies. $35M upfront payment. 
Via Benzinga
US Stocks Mixed, Dow Tumbles 150 Points
 
Via Benzinga
Topics Stocks
RAPT Therapeutics Announces $150 Million Private Placement
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Reports Third Quarter 2024 Financial Results
From RAPT Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Crude Oil Down 3%; Aramark Posts Upbeat Earnings
 
Via Benzinga
Nasdaq Moves Lower; Canaan Shares Surge
 
Via Benzinga
Rapt Therapeutics Stock Plummets, Terminates Asthma Trial Due To Patient's Liver Injury
RAPT Therapeutics stock falls after halting its zelnecirnon program following FDA clinical hold. Company shifts focus. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.